PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma (Tresto-Med)
Active Ingredient: Trestolone Acetate / MENT ($7\alpha$-methyl-19-nortestosterone)
Pharmacological Class: Synthetic $19\text{-Nortestosterone}$ Derivative / High-Potency Tissue-Selective Anabolic-Androgenic Agent
Tresto-Med by Bioniche Pharma contains Trestolone ($7\alpha$-methyl-19-nortestosterone / MENT), an extraordinarily potent synthetic anabolic steroid originally researched as a male hormonal contraceptive and androgen replacement agent. Engineered by Bioniche Pharma to deliver high tissue-selective anabolic activity, Tresto-Med rapidly drives skeletal muscle protein synthesis, accelerates fat loss, and supports nitrogen balance without conversion to dihydrotestosterone (DHT).
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
Trestolone features a unique $7\alpha$-methyl substitution on the steroidal ring structure. This methyl group sterically hinders interactions with $5\alpha$-reductase, preventing conversion into DHT or $5\alpha$-reduced metabolites. Despite being a $19\text{-nortestosterone}$ derivative, Bioniche Pharma Tresto-Med exhibits minimal binding affinity for progesterone and mineralocorticoid receptors. It does not bind significantly to Sex Hormone-Binding Globulin (SHBG), leaving a large percentage of circulating hormone unattached and bioavailable. While resistant to $5\alpha$-reduction, Trestolone undergoes aromatization to maintain essential androgen-dependent physiological functions similarly to endogenous testosterone.
Pharmacological profiling indicates an anabolic-to-androgenic rating ratio between $2300:650$ relative to testosterone, with animal model studies demonstrating up to $10\text{--}23\times$ greater anabolic potency than native testosterone and a $12\times$ stronger suppressive effect on the Hypothalamic-Pituitary-Testicular Axis (HPTA).
INDICATIONS & CLINICAL USE
- Investigational hormonal regimen for male contraception via rapid, reversible suppression of spermatogenesis.
- Therapeutic intervention for severe muscle wasting conditions, including Cachexia and age-related Sarcopenia.
- Primary male hypogonadism and androgen replacement therapy.
- Adjunctive treatment for rapid bone loss and osteoporosis under specialized medical oversight.
- Investigational applications in benign prostatic hyperplasia, prostate carcinoma management, and androgenic alopecia protocols.
CONTRAINDICATIONS
- Pediatric patients, adolescents, and minors under 18 years of age due to severe risks of unnaturally accelerated sexual maturation and premature epiphyseal plate closure.
- Confirmed or suspected prostate cancer or male breast carcinoma.
- Pregnancy and lactation due to extreme risks of fetal malformation, virilization, and endocrine toxicity.
- Patients with known hypersensitivity to Trestolone or inactive components in Bioniche Pharma formulations.
ADVERSE REACTIONS & SPECIAL PRECAUTIONS
- Severe HPTA Suppression: Due to its extreme potency, Bioniche Pharma Tresto-Med causes rapid and profound suppression of endogenous gonadotropin secretion (LH and FSH), resulting in temporary inhibition of natural testosterone production and spermatogenesis.
- Estrogenic Side Effects: Because Trestolone undergoes aromatization, monitoring for estrogen-mediated events (e.g., gynecomastia, fluid retention) is necessary.
- Metabolic & Systemic: Rapid acceleration of appetite and marked shifts in systemic metabolic rate. Unlike standard high-potency androgens, Trestolone demonstrates no significant polycythemic increases in hematocrit or hemoglobin levels.
DOSAGE & ADMINISTRATION
Due to the extreme potency and rapid therapeutic onset of Bioniche Pharma Tresto-Med, dosing protocols must be precisely calculated, initiated conservatively, and monitored under direct medical supervision based on clinical parameters and patient tolerance.
STORAGE & HANDLING
Store Bioniche Pharma products in a cool, dry place away from direct light exposure and excess heat. Do not refrigerate or freeze. Keep strictly out of reach and sight of children.